Objective To analyzed clinical efficacy and possible mechanism of DGMI)in treatment of patients with ACI.Methods 103 patients with ACI 2021 July to 2023 June were divided into observation group(n=52)and control group(n=51),The control group given routine western medicine,the observation group add DGMI therapy.2 weeks after treatment,the clinical efficacy,inflammatory factors,coagulation function,hemorheology,nerve injury factors and adverse reactions were compared between two groups.Results The observation group effective rate(94.23％)higher than that control group(74.51％)(x2/P=7.632/0.006);Serum CRP,IL-6,TNF-α lower than control group(t/P=8.990/＜0.001,7.025/＜0.001,4.546/＜0.001);PT,TT and APTT higher than control group(t/P=6.185/＜0.001,8.336/＜0.001,6.782/＜0.001),FIB lower than control group(t/P=6.683/＜0.001);Whole blood viscosity,plasma viscosity,platelet aggregation rate,hemato-crit lower than control group(t/P=3.553/0.001,5.667/＜0.001,11.933/＜0.001,10.497/＜0.001);Serum GFAP,SI00B,NSE lower than control group(t/P=6.364/＜0.001,5.707/＜0.001,4.847/＜0.001);the National Institutes of Health Stroke Scale(NIHSS)score was lower than that control group(t/P=9.707/＜0.001),the MMSE score and Barthel Index(BI)score were higher than that control group(t/P=7.847/0.00,11.421/＜0.001).There was no significant difference in adverse reactions be-tween two groups(13.46％vs.9.80％,x2/P=0.335/0.563).Conclusion DGMI can improve clinical efficacy of ACI patients,which may be related to antagonism of inflammatory reaction,improve coagulation function and hemorheology,inhibition of expression of nerve injury factors.
维普
万方数据
